Corticobasal Degeneration

Rare progressive neurological disorder characterized by Parkinsonism, cortical atrophy of multiple areas of the brain including the cerebral cortex and the basal ganglia, cognitive dysfunction and eye movement abnormalities.

Also Known As:

Networked: 525 relevant articles (5 outcomes, 42 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome)
2.	Alzheimer Disease (Alzheimer's Disease)
3.	Myoclonus (Nocturnal Myoclonus)
4.	Multiple System Atrophy
5.	Dementia (Dementias)

Experts

1.	Dickson, Dennis W: 20 articles (06/2022 - 10/2003)
2.	Hasegawa, Masato: 18 articles (01/2022 - 04/2004)
3.	Miller, Bruce L: 14 articles (01/2020 - 06/2008)
4.	Josephs, Keith A: 13 articles (06/2022 - 10/2003)
5.	Trojanowski, John Q: 13 articles (11/2019 - 06/2002)
6.	Seeley, William W: 11 articles (01/2020 - 03/2010)
7.	Yoshida, Mari: 9 articles (06/2022 - 10/2006)
8.	Boxer, Adam L: 9 articles (10/2020 - 08/2012)
9.	Lee, Virginia M-Y: 9 articles (11/2019 - 06/2002)
10.	Rabinovici, Gil D: 8 articles (01/2020 - 03/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Corticobasal Degeneration:

1.	Glucose (Dextrose)FDA LinkGeneric 12/01/2019 - "Localized low glucose metabolism in the unilateral cerebral lobe was seen in four patients by positron emission computed tomography (PET) examination, suggesting that PET is helpful for the diagnosis of corticobasal syndrome. " 11/26/1998 - "A positron emission tomography (PET) study on the regional cerebral glucose metabolism (rCMRglc) was performed in six patients with corticobasal degeneration (CBD). " 01/01/2017 - "Cerebral Glucose Metabolism and Dopaminergic Function in Patients with Corticobasal Syndrome." 04/01/2015 - "F-18 fluoro-d-glucose positron emission tomography/computed tomography in a patient with corticobasal degeneration." 04/01/2014 - "Furthermore, these findings strongly suggest that FDG PET imaging may assist the challenging clinical differentiation between hemi-PSP and corticobasal degeneration by depicting disease-specific patterns of regional cerebral glucose metabolism."
2.	tau Proteins (tau Protein)IBA 01/01/2022 - "Corticobasal Degeneration (CBD) is a rare neurological disease caused by the pathological accumulation of tau protein. " 05/01/2013 - "Corticobasal degeneration (CBD) is a disorder affecting cognition and movement due to a progressive neurodegeneration associated with distinctive neuropathologic features, including abnormal phosphorylated tau protein in neurons and glia in cortex, basal ganglia, diencephalon, and brainstem, as well as ballooned neurons and astrocytic plaques. " 01/01/2011 - "Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome." 01/01/2003 - "Cortico-basal degeneration is a rare degenerative disease connected with Tau protein pathology. " 01/01/2003 - "[Cortico-basal degeneration: the rare form of tau protein disease]."
3.	Amantadine (Aman)FDA LinkGeneric 08/01/2001 - "We reported a case of corticobasal degeneration of which praxic impairments were improved by administration of amantadine. " 08/01/2001 - "[A case of corticobasal degeneration of which movemental disturbances were improved by administration of amantadine]." 01/01/2015 - "Alien Limb Syndrome Responsive to Amantadine in a Patient with Corticobasal Syndrome."
4.	rho-Associated KinasesIBA 01/27/2016 - "Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration."
5.	Biomarkers (Surrogate Marker)IBA 01/01/2021 - "The aim of this study was to apply three different sets of criteria for CSF AD biomarker interpretation in a cohort of corticobasal degeneration (CBD) patients. " 12/12/2022 - "The Discourse Profile in Corticobasal Syndrome: A Comprehensive Clinical and Biomarker Approach." 06/13/2022 - "Neuropathology and emerging biomarkers in corticobasal syndrome." 01/01/2022 - "Corticobasal syndrome: A case of discordance between the clinical findings and the imaging biomarkers." 04/16/2021 - "Corticobasal syndrome: A case of discordance between the clinical findings and the imaging biomarkers."
6.	2- carbomethoxy- 8- (3- fluoropropyl)- 3- (4- iodophenyl)tropaneIBA 11/27/2023 - "This study demonstrated that the dual-phase FP-CIT PET is useful in differentiating CBS and IPD in the early stage of the disease, and a lower CP ratio of DAT imaging is highly informative for distinguishing between corticobasal degeneration and IPD." 10/01/2015 - "Corticobasal degeneration was considered as a possibility, but functional imaging studies including FP-CIT positron emission tomography were all normal. " 05/01/2013 - "To demonstrate that degeneration of substantia nigra neurons may occur at later stages of disease in some patients with corticobasal syndrome (CBS) who evidenced preserved nigrostriatal pathway at a baseline FP-CIT SPECT study. " 05/26/2021 - "Although the results of [123I] iodoamphetamine single-photon emission computed tomography suggested corticobasal degeneration, this was not observed on the [123I] FP-CIT single-photon emission computed tomography (SPECT) (DaTscan). " 01/01/2019 - "We investigated the usefulness of dual-phase F-FP-CIT PET imaging in 3 patients with corticobasal syndrome. "
7.	Protein Isoforms (Isoforms)IBA 01/01/2018 - "While pathology associated with the 4-repeat (4R) tau isoform is more abundant in corticobasal degeneration and progressive supranuclear palsy, both 3R and 4R tau isoforms accumulate in AD. " 01/01/2013 - "AGD has been tentatively classified in the 4R group (predominance of 4R tau isoforms) together with progressive supranuclear palsy and corticobasal degeneration. " 11/01/2008 - "These results parallel our earlier findings of differing C-terminal tau fragments in progressive supranuclear palsy and corticobasal degeneration, despite identical composition of tau isoforms. " 11/01/2007 - "Certain mutations alter the ratio between four (4R tau) and three (3R tau) repeat tau isoforms whereas cases with progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) mainly have 4R tau brain pathology. " 01/01/2000 - "In corticobasal degeneration and progressive supranuclear palsy, only phosphorylated 4R-tau isoforms aggregate and appear as a major tau doublet (tau 64 and 69). "
8.	Proteins (Proteins, Gene)FDA Link 01/01/2021 - "Elevated 18 kDa translocator protein labeling was observed in the subcortical brain areas of patients with corticobasal syndrome and progressive supranuclear palsy when compared with controls and was most pronounced in the globus pallidus internus, whereas only patients with corticobasal syndrome showed additionally elevated tracer binding in motor and supplemental motor areas. " 01/01/2021 - "The 18 kDa translocator protein PET was performed in 30 patients with corticobasal syndrome (68 ± 9 years, 16 women) and 14 patients with progressive supranuclear palsy (69 ± 9 years, 8 women), and 13 control subjects (70 ± 7 years, 7 women). " 01/01/2016 - "This study offers proof of concept that select lysosomal network proteins are differentially expressed in cerebrospinal fluid of Parkinson's disease, corticobasal syndrome and progressive supranuclear palsy. " 01/01/2022 - "τ protein increase correlated with cognitive impairment in progressive supranuclear palsy/corticobasal degeneration. " 01/01/2020 - "In this study, we examined the immunohistochemical distribution of BRCA1 and another DDR protein, p53-Binding Protein 1 (53BP1), in AD, Pick disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration, and frontotemporal dementia with parkinsonism linked to chromosome 17. "
9.	DNA-Binding Proteins (DNA Binding Protein)IBA 01/01/2022 - "Neuronal and glial inclusions comprising transactive response DNA-binding protein of 43 kDa (TDP-43) have been identified in the brains of patients with corticobasal degeneration (CBD), and a possible correlation between the presence of these inclusions and clinical phenotypes has been speculated. " 06/01/2021 - "We herein report a case of corticobasal syndrome (CBS) due to asymmetric degeneration of the motor cortex and substantia nigra with transactivation response DNA-binding protein of 43 kDa (TDP-43) proteinopathy, associated with Alzheimer's disease (AD) pathology. " 02/01/2019 - "She was found to have multiple pathological processes: corticobasal degeneration (CBD), Alzheimer's disease (AD), and TAR DNA-binding protein (TDP)-43 type A. " 06/01/2008 - "Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies." 01/01/2023 - "Seventeen patients with pathologically confirmed FTLD, including six with progressive supranuclear palsy, three with corticobasal degeneration, eight with TAR DNA-binding protein 43 (FTLD-TDP), and 11 with pathologically confirmed AD, were investigated. "
10.	Amyloid beta-PeptidesIBA 02/01/2006 - "The co-localization of amyloid beta (Abeta) and phosphorylated tau in astrocytes in a patient with corticobasal degeneration is described. " 10/15/2005 - "Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration." 01/01/2021 - "Using immunoprecipitation and mass spectrometry methods, we compared CSF T217 phosphorylation occupancy (pT217/T217) and amyloid-beta (Aβ) 42/40 ratio in cognitively normal individuals and those with symptomatic AD, progressive supranuclear palsy, corticobasal syndrome, and sporadic and familial frontotemporal dementia. " 07/01/2009 - "An abundance of tau inclusions, in the absence of beta-amyloid deposits, defines Pick's disease, progressive supranuclear palsy, corticobasal degeneration and other diseases. " 01/01/2001 - "Prominent filamentous tau inclusions and brain degeneration in the absence of beta-amyloid deposits are also hallmarks of neurodegenerative tauopathies exemplified by sporadic corticobasal degeneration, progressive supranuclear palsy, and Pick's disease, as well as by hereditary frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). "

Therapies and Procedures

1.	Therapeutics 01/01/2014 - "These behavioural, structural and functional results converge to reveal the frontal network for altered awareness and control of voluntary action in corticobasal syndrome, and provide candidate markers to evaluate new therapies. " 07/01/1998 - "Clinical presentation and pharmacological therapy in corticobasal degeneration." 01/01/2021 - "Spinal Cord Stimulation Therapy for Gait Dysfunction in Two Corticobasal Syndrome Patients." 08/10/2003 - "[Diagnosis and therapy for progressive supranuclear palsy and corticobasal degeneration]." 10/01/2007 - "Therapy developed for myoclonus in this model may be helpful for myoclonus from other etiologies such as corticobasal degeneration, Lewy-body disorders, Creutzfeld-Jacob disease, Alzheimer's disease."
2.	Transcranial Magnetic Stimulation 07/01/2000 - "[Intracranial inhibitory mechanisms in clinically diagnosed corticobasal degeneration: a study of a silent period followed by transcranial magnetic stimulation]." 06/01/2015 - "In corticobasal syndrome, transcranial magnetic stimulation showed a reduction cortical inhibitory phenomenon potentially reversed transiently by slow repetitive transcranial magnetic stimulation. " 06/01/2015 - "With transcranial magnetic stimulation, we studied two corticobasal syndrome patients. " 06/01/2015 - "We explored with transcranial magnetic stimulation the motor cortical excitability in corticobasal syndrome, and the effects of slow repetitive transcranial magnetic stimulation. " 06/01/2015 - "Effects of slow repetitive transcranial magnetic stimulation in patients with corticobasal syndrome."
3.	Transcranial Direct Current Stimulation 09/01/2015 - "Left parietal cortex transcranial direct current stimulation enhances gesture processing in corticobasal syndrome." 01/01/2015 - "Anodal transcranial direct current stimulation of parietal cortex enhances action naming in Corticobasal Syndrome." 01/01/2023 - "Neurologic music therapy combined with EEG-tDCS for upper motor extremity performance in patients with corticobasal syndrome: Study protocol for a novel approach."
4.	Music Therapy 01/01/2023 - "Neurologic music therapy combined with EEG-tDCS for upper motor extremity performance in patients with corticobasal syndrome: Study protocol for a novel approach."
5.	Spinal Cord Stimulation 01/01/2021 - "Spinal Cord Stimulation Therapy for Gait Dysfunction in Two Corticobasal Syndrome Patients."